Study #2023-0794
A multi-site Break Through Cancer trial: Phase II study investigating dual inhibition of BCL2 and Menin in AML MRD using the combination of Venetoclax and Revumenib
MD Anderson Study Status
Enrolling
Treatment Agent
Venetoclax, Revumenib
Description
To learn if the combination of venetoclax and revumenib can help to control MRD-positive AML.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Acute Myeloid Leukemia
Study phase:
Phase II
Physician name:
Ghayas Issa
Department:
Leukemia
For general questions about clinical trials:
1-833-731-1107
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.